logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9040549 B1

PDFFull Text
Date of Patent:
May. 26, 2015

Filed:

Apr. 11, 2013

Thiopyrimidine-based compounds and uses thereof

Applicant:

Cytopia Research Pty Ltd., Richmond, Victoria, AU;

Inventors:

David Gerard Bourke, Donvale, AU;

Xianyong Bu, Parkville, AU;

Christopher John Burns, Caulfield North, AU;

Anthony Nicholas Cuzzupe, Parkville, AU;

John Thomas Feutrill, Rosanna, AU;

Tracy Leah Nero, St. Albans, AU;

Beata Maria Blannin, Seabrook, AU;

Jun Zeng, Scoresby, AU;

Shaun Patrick Gaynor, Richmond, AU;

Assignee:

YM Biosciences Australia Pty Ltd., Foster City, CA (US);

Attorney:

Yu-Ming Dammann

Primary Examiner:

Erich A Leeser

Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61K 31/506 (2006.01); C07D 413/12 (2006.01); C07D 487/00 (2006.01); C07D 487/02 (2006.01); C07D 239/38 (2006.01); C07D 239/47 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 31/505 (2013.01); C07D 487/00 (2013.01); C07D 487/02 (2013.01); A61K 31/506 (2013.01); C07D 239/38 (2013.01); C07D 239/47 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.

Find Patent Forward Citations

Loading…